Roche stakes its KRAS claim
Phase 1 data for divarasib in lung and colorectal cancers look good versus Lumakras and Krazati’s earlier showings.
More doubts swirl around Lumakras
With sales of the Amgen KRAS inhibitor flatlining an advisory panel is called to discuss its continued US approval.
Exelixis claims a label-expanding Cabo success at last
However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.
Mirati secures an independent future
Mirati raises $300m as its chief exec departs. What’s not to like?
Lilly calls time on IDH1/2 inhibition
Servier's vorasidenib had shown promise at ASCO, but Lilly's dual IDH project LY3410738 leaves the pipeline.
Lung cancer switch does the job for Black Diamond
First data with the biotech’s new EGFR project prompts a 236% share price bump.
